Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
108 results about "C-peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The connecting peptide, or C-peptide, is a short 31-amino-acid polypeptide that connects insulin's A-chain to its B-chain in the proinsulin molecule. In the context of diabetes or hypoglycemia, a measurement of C-peptide blood serum levels can be used to distinguish between different conditions with similar clinical features.
Insulin production methods and pro-insulin constructs
InactiveUS20080146492A1Reduce eliminateImprove efficiencyBacteriaSugar derivativesInsulin activityImproved method
Novel pro-insulin having specific amino acid and / or nucleic acid modifications suitable for improved methods of insulin production are provided. Novel and highly efficient processes for preparing the pro-insulin preparations and preparations containing them are also disclosed. The novel pro-insulin preparations may be converted into human insulin useful in therapeutic preparations. Novel peptides of the C-peptide, and N terminus, including RREAEALQVGQVELGGGPGAGSLQPLALEGSLQAR (SEQ ID NO: 32), and MHHHHHHGGR (SEQ ID NO: 2) respectively are provided, as well as the unique nucleic acid molecules encoding them.
Owner:AGILA BIOTECH PVT LTD
C-peptide specific assay procedure
InactiveUS6929924B2Highly accurate C-peptideStrong specificityAnimal cellsBiological material analysisC-peptideProinsulin
The present invention relates to a specific C-peptide assay method which can eliminate all interference due to proinsulin and its intermediates, in particular des-31,32-proinsulin and / or des-64,65-proinsulin. It also relates to antibodies for carrying out this assay.
Owner:BIO RAD EURO GMBH
Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
The present invention relates to a peptide having one or more stable, internally-constrained HBS α-helices, where the peptide mimics at least a portion of a class I C-peptide helix or at least a portion of a class I N-peptide helix of a viral (e.g., HIV-I) coiled-coil assembly. Methods of inhibiting viral infectivity of a subject by administering these peptides are also disclosed.
Owner:NEW YORK UNIV
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
InactiveUS6913903B2Less expensiveHigh yieldPeptide/protein ingredientsDepsipeptidesOligomerProinsulin
Owner:BIOCON LTD
C-peptide micropore plate type magnetic granule chemoluminescence immunoassay measuring kit and preparation method thereof
InactiveCN101545909ALow costHigh sensitivityChemiluminescene/bioluminescenceBiological testingMonoclonal antibodyPolyclonal antibodies
The invention discloses a C-peptide micropore plate type magnetic granule chemoluminescence immunoassay measuring kit and a preparation method thereof. The kit comprises: (1) a C-peptide calibration sample, (2) magnetic granules coated by a C-peptide monoclonal antibody, (3) another monoclonal antibody or a polyclonal antibody marked by horse radish peroxidase (HRP), (4) a micropore plate, (5) washing solution and (6) chemoluminescence substrate solution on which the enzyme acts. The preparation method for preparing the kit further comprises the steps of preparing the calibration sample, preparing the magnetic granules coated by the C-peptide antibody, marking the C-peptide antibody with the horse radish peroxidase (HRP), preparing the washing solution and preparing the chemoluminescence substrate solution. The kit is simple, convenient, fast, sensitive, stable and the like.
Owner:北京科美东雅生物技术有限公司
Chemosensory Receptor Ligand-Based Therapies
Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.
Owner:AMBRA BIOSCI LLC
Method for detecting content of C peptide in human serum, kit used by method and preparation method thereof
InactiveCN104749375AConsistent specificitySame sensitivityDisease diagnosisBiological testingC-peptideSurface-active agents
The invention relates to a latex enhanced immunoturbidimetry kit for measuring the content of C peptide in human serum, a preparation method of the kit and a method for detecting the content of C peptide in human serum by use of the kit. The kit comprises a first reagent, a second reagent and a calibrator, wherein the first reagent contains buffer solution, electrolyte, a surface active agent, a stabilizing agent, a reaction enhancer and a preservative; the second reagent contains buffer solution, electrolyte, a surface active agent, a preservative and anti-human C peptide antibody enveloped sensitization polystyrene latex particles; and the calibrator contains buffer solution, a surface active agent, a stabilizing agent, a preservative and human C peptide protein. Compared with the existing kit used clinically, the kit provided by the invention has strong specificity, high sensitivity and high accuracy, the kit is suitable for biochemical analyzers of common detection mechanism, has short detection time, can be operated conveniently, has low detection cost, has no radioactive contamination, and is suitable for popularization and application clinically.
Owner:SHANGHAI CHUANZHI BIOTECH CO LTD
Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression.
Owner:CEDARS SINAI MEDICAL CENT
C-peptide chemiluminescence immunodetection kit, preparation method and detection method therefor
InactiveCN109239356ARealize detectionLow costChemiluminescene/bioluminescenceBiological testingBiotin-streptavidin complexPeptide antigen
The invention discloses a C-peptide chemiluminescence immunodetection kit, a preparation method and a detection method therefor, belongs to the field of the immunoassay, and solves the problems of lowsensitivity, long reaction time, and high cost of an existing C-P detection method. The kit comprises magnetic particles coated by the streptavidin; the C peptide antibody labeled by the biotin; theC peptide antibody labeled by the acridinium ester; the wash buffer; the chemoluminescence pre-trigger solution; a calibrator; and a quality control product. The detection method is as follows: the C-peptide antigen in the sample is immunologically reacted with the C-peptide antibody labeled by the biotin and the C peptide antibody labeled by the acridinium ester to form a biotin-C peptide antibody-C peptide antigen-C peptide antibody-acridinium ester solvent; the magnetic particles coated by the streptavidin are combined with the biotin to form a magnetic bead-streptavidin-biotin-C peptide antibody-C peptide antigen-C-peptide antibody-acridinium ester complex; and the concentration of the C peptide is calculated by adding the washing buffer and the like. According to the C-peptide chemiluminescence immunodetection kit, the preparation method and the detection method therefor, the sensitivity is high, the specificity is good, the reaction time is short, and the cost is low.
Owner:DIRUI MEDICAL TECH CO LTD
Insulin and C peptide double-tagging determination kit
InactiveCN102419373ASolve the problem of unstable storage at 28°CSolve the unstable placementBiological testingFluorescence/phosphorescenceC-peptideEuropium
The invention relates to an insulin and C peptide double-tagging kit, especially relates to a kit for determining insulin and C peptide by a double-tagging time resolution immunofluorescence and by using dried blood spots specimen on filter paper as a sample, and provides a preparation method of europium marked anti C peptide antibody and samarium marked insulin antibody. The kit can carry out simultaneous quantitative detections on two landmarks of insulin and C peptide through one detection, and the sample of dried blood spots specimen on filter paper solves a problem of unstable insulin and C peptide in a serum sample. The kit of the invention can be widely applied to various researching field of aided diagnosis and patient's condition detection, clinical drug guidance and prognosis of diabetes.
Owner:GUANGZHOU DARUI BIOTECH
Methods for quantitation of insulin levels by mass spectrometry
ActiveUS20160282328A1Improve accuracyComponent separationMicrobiological testing/measurementPurification methodsLevel insulin
Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and / or purification methods coupled with tandem mass spectrometric or high resolution / high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and / or purification methods coupled with tandem mass spectrometric or high resolution / high accuracy mass spectrometric techniques.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC
Methods and kits for preventing hypoglycemia
InactiveUS7855177B1Reduce riskReduce incidencePeptide/protein ingredientsMetabolism disorderExcessive weight gainGlycemic
Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
Owner:CEBIX
HIV-1 p-17 peptide fragments, compositions containing and methods for producing and using same
Owner:VIRAL TECH
Glargine proinsulin and methods of producing glargine insulin analogs therefrom
Glargine proinsulin sconstructs that have a modified C-peptide amino acid and / or nucleic acid sequence for producing glargine insulin analogs are provided. Highly efficient processes for preparing the glargine insulin analogs and improved preparations containing the glargine insulin analogs prepared according to the methods described herein are also provided.
Owner:ELONA BIOTECH
Composite probiotic liquid for preventing diabetes and controlling body weight and preparation method thereof
InactiveCN106176833APromote growthLow residual glucoseMetabolism disorderUnknown materialsBacillus licheniformisSide effect
The invention discloses a composite probiotic liquid for preventing diabetes and controlling body weight and a preparation method thereof. The composite probiotic liquid contains saccharomyces boulardii, acetobacter xylinum, lactobacillus plantarum, bifidobacterium adolescentis, bacillus licheniformis, clostridium butyricum, arabinose, xylooligosaccharide and bacterial cellulose and the like. After probiotics and prebiotics of the composite probiotic liquid enter the human body, the absorption of glycogens such as glucose by the intestinal tract can be quickly reduced, and thus the body weight is controlled and blood glucose is reduced. Clinical test results indicate that for a patient who orally administers the composite probiotic liquid, it is determined preliminarily that the composite probiotic liquid is more excellent than pure application of metformin in the aspects of time for blood glucose to meet the standard, sugar tolerance improvement, insulin improvement and c-peptide release, and has a remarkable weight loss effect. In addition, the composite probiotic liquid indeed has curative effects in the aspects of functions of improving insulin resistance and protecting islet cells and has no side effect.
Owner:北京鸿保康微生物技术发展有限公司
Compositions and methods of treating diabetes
InactiveUS20100216693A1Marked depressionReduce aggregationPeptide/protein ingredientsMetabolism disorderC-peptideInsulin Analogue
Owner:CREATIVE PEPTIDES SWEDEN
Method of Differentiating Stem Cells
InactiveUS20110008819A1Effectively lead to differentiationPancreatic cellsMicrobiological testing/measurementGerm layerScreening method
There is provided an improved efficient method for differentiating stem cells into pancreatic endoderm cells and pancreatic hormone expressing and secreting cells which express Pdx-1 and C-peptide. The invention further provides screening methods for detecting factors of interest that will affect the differentiation of the stem cells into pancreatic endoderm cells.
Owner:ES CELL INT
Oxyntomodulin (OXM) analogue and application thereof
InactiveCN106986924AHigh activityConvenient purification workPeptide-nucleic acidsPeptide/protein ingredientsSynthesis methodsFreeze-drying
The invention relates to a novel oxyntomodulin (OXM) analogue and a synthesis method thereof. A terminal C of natural OXM is subjected to Ex-4, GLP-1 and Lixisenatide partial terminal C peptide sequence substitution to obtain the OXM analogue with optimal pharmacological activity, synthesis of a peptide chain is rapidly implemented by an orthogonal protection strategy solid phase synthesis method, a coarse product is purified and freeze-dried to obtain the OXM analogue.
Owner:CHINA PHARM UNIV
Calibration product stabilizer, detection kit for determining C peptide and detection method
ActiveCN109917134ALow costImprove responseChemiluminescene/bioluminescenceBiological testingC-peptideReaction curve
The invention belongs to the technical field of biomedical examination, and particularly relates to a calibration product stabilizer, a C peptide determination detection kit and a detection method. The kit comprises a calibration product, a reagent 1, a reagent 2, a reagent R3 and a reagent R4. According to the kit, an acridinium ester-labeled anti-C peptide antibody, an antigen and a horse radishperoxidase-labeled anti-C peptide antibody are utilized to form an antibody-antigen-antibody compound. A triggering agent is added into the compound without a washing process, the compound is continuously detected for a period of time, the peak area is calculated every 0.02-0.05 S, and a dosage-reaction curve is made by using C peptide with known concentration and the calculated peak area; and the content of the C peptide in the sample to be detected is calculated according to the curve. The kit for detecting the C peptide by adopting the spatial proximity chemiluminiscence method provided bythe invention has the advantages of strong calibration product stability, strong reagent anti-interference capability, high accuracy, good specificity and wide linear range, and is suitable for beingused by medical and research institutions at all levels in combination with instrument measurement.
Owner:GUANGZHOU JINDE BIOTECH
Methods for quantitation of insulin levels by mass spectrometry
Owner:QUEST DIAGNOSTICS INVESTMENTS INC
Human relaxin 2 precursor and preparation method thereof
InactiveCN102603888AIncrease secreted expressionReduced Excision CostsFungiRelaxinsSecretion expressionC-peptide
The invention relates to a human relaxin 2 precursor and a preparation method thereof. According to the human relaxin 2 precursor, a B chain and an A chain of a natural human relaxin 2 are connected through an AsnGlyPheAsnGly artificial C peptide in a B-C-A order, so as to form a structure of a non-natural human relaxin 2 precursor. An amino acid sequence of the human relaxin 2 precursor is shown by a sequence 1 in a sequence list and is named as rhR2. According to the human relaxin 2 precursor and an optimized gene thereof, provided by the invention, a secreted expression amount of the human relaxin 2 precursor in pichia pastoris is greatly improved. The C peptide of the human relaxin 2 precursor is removed by using cheap hydroxyl amine rather than expensive TPCK (Tosyl-Phenylalanine Chloromethyl-Ketone)-trypsinase, so that the cost of removing the C peptide is reduced.
Owner:HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
Chemiluminescent examining method for insulin content and C-peptide content in human blood serum
InactiveCN1963505AAvoid disadvantagesAvoid harmChemiluminescene/bioluminescenceBiological testingSerum igeTest agent
This invention relates to one human serum insulin content and C-peptide chemical test method in clinical serum immune test technique, which uses human serum insulin quantitative test agent case to test human serum insulin content and human serum C-peptide agent case to test human serum C-peptide content.
Owner:AUTOBIO DIAGNOSTICS CO LTD
Methods for quantitation of insulin and c-peptide
Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and / or purification methods coupled with tandem mass spectrometric or high resolution / high accuracy mass spectrometric techniques.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC
Method for prevention or treatment of diabetic angiogenesis impairment using C-peptide
Disclosed are a method and a composition for the prevention or treatment of diabetic angiogenesis impairment or diabetic wound-healing impairment, using C-peptide. Found to be able to induce angiogenesis through chemotatic migration of endothelial cells, cell migration to wounded areas, capillary-like network formation, and ERK1 / 2 and Akt phosphorylation and NO production, C-peptide has prophylactic or therapeutic applications in a broad spectrum of various diabetic complications including diabetic angiogenesis impairment.
Owner:AMOLIFESCI CO LTD +1
Chemiluminescence assay kit for detecting C-peptide content in serum and detection method
InactiveCN109297953AStrong specificityImprove stabilityChemiluminescene/bioluminescenceBiological testingPh regulationMicroparticle
The invention belongs to the field of medical detection and discloses a chemiluminescence assay kit for detecting C-peptide content in serum and a detection method. The assay kit comprises: an M reagent, an R reagent, a C-P calibrator, a pH adjuster, a reaction enhancer, and a chemiluminescent substrate. The M reagent contains a magnetic particle coated with a C peptide-biotinylated antibody at aconcentration of 2[mu]g / mL, and a Tris buffer solution at a concentration of 0.2mol / L. The R reagent contains a C-P-AP labeled antibody at a concentration of 1[mu]g / mL, and a Tris buffer solution at aconcentration of 0.1mol / L. The C-P calibrator comprises two different concentrations of C-peptide samples and a 0.1mol / L concentration of Tris buffer solution. The assay kit for detecting C-peptide has advantages of strong specificity and good stability, thereby improving the sensitivity and specificity of the detection; has a good stability in the whole system; is simple in operation; and is suitable for use with a clinical full automatic chemiluminescence assay instrument.
Owner:HONGKUI BIOLOGICAL CHINA CO LTD
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
InactiveUS7166571B2Less-expensive and high yieldingStrong specificityPeptide/protein ingredientsDepsipeptidesOligomerC-peptide
Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.
Owner:BIOCON LTD
Competitive latex-particle-enhanced immunoturbidimetric assay kit for C-peptide and preparation method thereof
ActiveCN102680713AEfficient detectionThe detection method is simpleBiological testingLatex particleC-peptide
The invention discloses a competitive latex-particle-enhanced immunoturbidimetric assay kit for C-peptide and a preparation method thereof, and solves the problems of high difficulty in C-peptide assay, long time for assay and the like in the current sandwich method. The kit disclosed by the invention is composed of latex particles and reaction buffer, and is characterized in that the latex particles are coated with the following artificially-synthesized amino acid sequences: EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ-X, and X consists of 2 to 4 Ks. The invention further provides a preparation method of the kit. The kit disclosed by the invention has the advantages of high accuracy, short time for assay, high reliability, etc.
Owner:BYRON DIAGNOSTICS SHANGHAI
Anti-C-peptide monoclonal antibody and use thereof in detection of C-peptide content
ActiveCN103074302ASolve the small molecular weightFix stability issuesImmunoglobulins against animals/humansMicroorganism based processesSerum igeMicrobiology
The invention discloses an anti-C-peptide monoclonal antibody and a use thereof in detection of C-peptide content. According to the invention, C-peptide-GST and C-peptide-Trx are used as immunogens, two hybridoma cell strains are obtained by cell fusion technique-based screening, the microbial preservation numbers of the two hybridoma cell strains are respectively CGMCC NO. 6804 and CGMCC NO.6805, two monoclonal antibodies secreted by the two hybridoma cell strains can mutually matched, the content of C-peptide in serum is detected by double-antibody sandwich ELISA method, and the detection result has high accuracy and sensitivity.
Owner:BEIJING LEADMAN BIOCHEM
Method for constructing related intestinal canal-pancreatic islet regulation axis function evaluation model and application of model
The invention provides a method for constructing a related intestinal canal-pancreatic islet regulation axis function evaluation model. The method includes: allowing a subject to take different oral hypoglycemic drugs or blank control in different stages, then performing intravenous-oral dual hyperglycemic clamp tests on the subject in each stage, drawing an area under the curve for a serum insulin value, a C-peptide value, a plasma glucagon value and an active glucagon-like polypeptide-1 (GLP-1) value acquired through the dual hyperglycemic clamp tests in each stage, and applying Metlab to perform 3D (three-dimensional surface fitting on the areas under the curve in one-to-one correspondence to obtain the related intestine-pancreas axis function evaluation model. By the method, two-phase insulin secretion patterns in intravenous-oral glucose stimulation states can be evaluated and compared accurately, besides, intestinal canal hormone effect and insulin-glucagon secretion can be related quantitatively, and accordingly an accurate intestine-pancreas axis effect model evaluation system is obtained.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
ActiveUS20050080001A1Less expensiveHigh yieldPeptide/protein ingredientsDepsipeptidesOligomerC-peptide
Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also described as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates are also described.
Owner:BIOCON LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap